Switzerland’s 2022 medical cannabis reform improved patient access by removing federal approval requirements, but challenges remain. MEDCAN highlights barriers including limited prescribing doctors, inconsistent insurance coverage, and high costs. Patients report improved quality of life through regulated treatments, while the association calls for better medical knowledge, transparency, and broader acceptance of cannabis-based therapies.